<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PP</journal-id><journal-title-group><journal-title>Pharmacology &amp; Pharmacy</journal-title></journal-title-group><issn pub-type="epub">2157-9423</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/pp.2016.710047</article-id><article-id pub-id-type="publisher-id">PP-70877</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Chemistry&amp;Materials Science</subject><subject> Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Anticoagulant, Antiplatelet and Antianemic Effects of Citrus paradisi (Grape Fruit) Juice in Rabbits
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Neelam</surname><given-names>Mallick</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Rafeeq</surname><given-names>Alam Khan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Azra</surname><given-names>Riaz</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Syeda</surname><given-names>Afroz</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan</addr-line></aff><aff id="aff1"><addr-line>Department of Pharmacology, Ziauddin University, Karachi, Pakistan</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>rkhan1959@gmail.com(RAK)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>09</month><year>2016</year></pub-date><volume>07</volume><issue>10</issue><fpage>397</fpage><lpage>406</lpage><history><date date-type="received"><day>August</day>	<month>14,</month>	<year>2016</year></date><date date-type="rev-recd"><day>Accepted:</day>	<month>September</month>	<year>24,</year>	</date><date date-type="accepted"><day>September</day>	<month>27,</month>	<year>2016</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   Medicinal plants are under continuous analysis worldwide to explore new medication to treat atherosclerosis and cardiovascular diseases. Citrus fruits have displayed utmost antioxidant activity, particularly flavonoids in Citrus paradisi have exhibited strong antioxidant and anti-inflammatory characteristics. This study was intended to examine effects of C. 
   paradisi
    on blood coagulation and anticoagulation at doses of 0.1, 0.3 and 0.5 ml/kg. Highly significant increase in thrombin time (TT) and substantial decline in fibrinogen (Fb) level was noticed as related to control. There was substantial increase in TT, prothrombin time (PT) and activated partial thromboplastin time (aPTT) and noteworthy decrease in Fb level by warfarin. C. 
   paradisi
    at 0.3 ml/kg considerably inhibited aggregation of platelet by collagen, adenosine phosphate, arachidonic acid and epinephrine, while there was also substantial rise in Protein C, TAT complex, RBC and hemoglobin concentration. In conclusion, these results suggest that the addition of C. 
   paradisi
    to the diet of patients at risk of developing cardiovascular events could significantly decrease the morbidity or mortality in these patients due to high contents of phytochemicals like naringin, hesperidin, limonene and other flavonoids. 
  
 
</p></abstract><kwd-group><kwd>Anticoagulant</kwd><kwd> Antiplatelet</kwd><kwd> Antianemic</kwd><kwd> Grape Fruit</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>It has been documented that individuals consuming citrus fruits regularly have decreased risk of cardiovascular disease and ischemic stroke [<xref ref-type="bibr" rid="scirp.70877-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.70877-ref2">2</xref>] . Grapefruit is considered among the most widely consumed citrus fruits in the form of juice. The nutrients and bioactive phytochemicals present in grapefruit juice include sugars, organic acids, flavonoids and other phenolic compounds [<xref ref-type="bibr" rid="scirp.70877-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.70877-ref4">4</xref>] .</p><p>Flavonoids are widely dispersed group of polyphenol compounds with health-related characteristics that are based on their antioxidant activity, e.g. inhibition of platelet aggregation, anticancer, anti-inflammatory and antiviral activities. The flavonoids present in Citrus are Flavanones, flavones, and flavonols, although flavones and flavonols are found in low concentrations as compared to flavanones, but are potent antioxidants and free radical scavengers [<xref ref-type="bibr" rid="scirp.70877-ref5">5</xref>] .</p><p>Numerous unique threats have been proposed as probable measures for better revealing of subclinical atherosclerosis; however clinically attention has been paid to parameters like lipoprotein (a), apolipoprotein (apo) A-I, apo B-100, C-reactive protein (CRP) and fibrinogen to reveal risk factors for systemic atherosclerosis [<xref ref-type="bibr" rid="scirp.70877-ref6">6</xref>] . Moreover, it has been indefinite whether screening for some of these unique biomarkers significantly expands risk estimation over that related to standard lipid screening [<xref ref-type="bibr" rid="scirp.70877-ref7">7</xref>] - [<xref ref-type="bibr" rid="scirp.70877-ref9">9</xref>] .</p><p>Most significant reasons for atherosclerosis and cardiovascular diseases are flaws in coagulation and thrombosis [<xref ref-type="bibr" rid="scirp.70877-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.70877-ref11">11</xref>] . Prevention and treatment of thrombogenic state have been investigated through coagulation and anticoagulant agents [<xref ref-type="bibr" rid="scirp.70877-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.70877-ref13">13</xref>] . Various factors of blood coagulation have been found to be associated with cardiovascular disease as well as hemostasis e.g. augmented level of factor VIII, von Willebr and factor and platelet activation [<xref ref-type="bibr" rid="scirp.70877-ref14">14</xref>] .</p><p>The role of flavonoids and polyphenols has been studied to prevent and treat cardiovascular diseases due to several reasons [<xref ref-type="bibr" rid="scirp.70877-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.70877-ref16">16</xref>] including antioxidant and anti-infla- mmatory activity [<xref ref-type="bibr" rid="scirp.70877-ref17">17</xref>] - [<xref ref-type="bibr" rid="scirp.70877-ref19">19</xref>] , as increase dietary intake of antioxidants may prevent atherosclerosis [<xref ref-type="bibr" rid="scirp.70877-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.70877-ref21">21</xref>] , since increased cholesterol and occlusion is correlated [<xref ref-type="bibr" rid="scirp.70877-ref22">22</xref>] - [<xref ref-type="bibr" rid="scirp.70877-ref24">24</xref>] .</p><p>Grape fruits (C. paradisi) have high vitamin C and potassium and are worthy source of calcium, folate, iron and other minerals. They also hold protective plant chemicals like phenolic acid, limonoids, monoterpenes, terpenes and bioflavonoids that are prevents cancer and heart diseases. Naringin is the chief bioflavonoid in grapefruit having diverse pharmacological affects e.g. antioxidant, hypolipidemic [<xref ref-type="bibr" rid="scirp.70877-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.70877-ref26">26</xref>] and anticarcinogenic activity [<xref ref-type="bibr" rid="scirp.70877-ref5">5</xref>] .</p><p>Recently, thrombin has been found to have dual role and all the anti-inflammatory effects of grape fruits contribute towards anti-coagulant state in the body [<xref ref-type="bibr" rid="scirp.70877-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.70877-ref28">28</xref>] . Thus current study was aimed to measure anticoagulant, hematological and antithrombotic effects of C. paradisi to endorseits preventive and therapeutic role in various situations; hence thrombin and prothrombin time, activated partial thromboplastin time (aPTT), fibrinogen level (Fb), platelet function, thrombin antithrombin (TAT) complex and protein C (PC) were determined to evaluate the effects of these parameters on blood in rabbits.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Citrus paradisi Juice</title><p>Grapefruit (C. paradisi) was bought from the local vendors. The fruit was recognized by Prof. Anjum Parveen (Director, Plant Conservation Center; University of Karachi) and voucher sample no C.P 09-10 was deposited in the Department of Pharmacognosy, University of Karachi. The fruit was peeled and pressed to obtain fresh juice which was used promptly after filtration. The fresh juice was then given by mouth in three doses i.e. 0.1, 0.3 and 0.5 ml/kg as per body weight of the animals.</p></sec><sec id="s2_2"><title>2.2. Animals</title><p>Study was conducted on 60, healthy white rabbits of either sex with average body weight 1300 &#177; 50 grams after agreement from board of advance studies and research, University of Karachi. Steel rod bottom cages were used for individual housing of the rabbits with unrestricted contact to diet and water at a temperature 23˚C &#177; 2˚C, humidity 50% - 60% with 12 hour light/dark cycle.</p></sec><sec id="s2_3"><title>2.3. Dosing</title><p>Animals were allocated in 6 groups having 10 rabbit’s each. C. paradisi was administered to three groups in the doses of 0.1, 0.3 and 0.5 ml/kg respectively for 30 days. Animal group served as normal control received saline in doses equivalent to their body weights, while remaining two groups received standard drugs aspirin and warfarin. Aspirin was administered on once daily basis (150 mg/kg) suspended in normal saline for 6 days per week [<xref ref-type="bibr" rid="scirp.70877-ref29">29</xref>] , warfarin was given for 6 days only in distilled water i.e. 5 mg/kg first 3 days and 10 mg/kg next 3 days [<xref ref-type="bibr" rid="scirp.70877-ref30">30</xref>] . Drugs and juices were administered via gastric intubation. 3. Prepare Your Paper before Styling.</p></sec><sec id="s2_4"><title>2.4. Sample Collection</title><p>The National Committee for Clinical Laboratory Standards (NCCLS) approved guidelines H21-A3 were followed for Sample collection and handling [<xref ref-type="bibr" rid="scirp.70877-ref31">31</xref>] . Blood samples were gathered in EDTA and 3.8% tri sodium citrate containing tubes in the ratio of 9:1 and gel tubes at the end of dosing period from ear vein. Centrifugation of Blood samples was done to separate plasma at 2000 x g for 10 min in Humax 14 K (Human, Germany).</p></sec><sec id="s2_5"><title>2.5. Coagulation and Hematological Testing</title><p>Coagulation parameters were determined by Huma clot duo (Human, Germany) using standard reagent kits provided by Human, Germany. Turbidimetric clot were detected and coagulation endpoint was assessed in plasma. 100 ul thrombin reagent was used to incubate 200 ul plasma for TT; 100 ul plasma with 200 ul pre-warmed thromboplastin reagent was incubated for PT. While 100 ul plasma was incubated for 1 to 2 min at 37˚C with 100 ul aPTT-EL reagent then 100 ul CaCl2 was added for activated partial thromboplastin time. All plasma samples were incubated at 37˚C for 3 min. Clauss method [<xref ref-type="bibr" rid="scirp.70877-ref32">32</xref>] was used to evaluate Fb concentration as defined by McNerlan et al. [<xref ref-type="bibr" rid="scirp.70877-ref33">33</xref>] .</p><p>Fully automated hematology analyzer, Huma Count (Human, Germany) was employed to study hematological parameters i.e. red blood cell count (RBC), white blood cell count (WBC), platelet count (PLT), Hematocrit (Ht), hemoglobin (Hb), mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH).</p><p>Helena Agg RAM aggregometer (Helena Laboratories Corp, Beaumont, TX, USA) was used for the assay of platelet aggregation. Plasma separated from blood was considered as platelet rich plasma (PRP), how-ever further centrifugation of blood for 10 - 15 minutes at 1600 - 2000 rpm yielded platelet-poor plasma (PPP). Standardization of PRP (approx. 250,000/mm<sup>3</sup>) with autologous PPP was done as required [<xref ref-type="bibr" rid="scirp.70877-ref34">34</xref>] .</p><p>Platelet reactivity was found at 37˚C for 10 min [<xref ref-type="bibr" rid="scirp.70877-ref35">35</xref>] , for untreated PRP mixed with the aggregation reagent, the absorbance represents 0% aggregation; the absorbance denotes 100% of PPP control. Epinephrine (300 μM), Arachidonic acid (500 μg/ml), Adenosine diphosphate (20 μM) and Collagen (10 μg/ml), were used as platelet aggregation inducers. Platelet aggregation in samples was measured as described by Riaz et al. [<xref ref-type="bibr" rid="scirp.70877-ref36">36</xref>] . Pipette was used to measure and pour 450 μl PRP into cuvettes which were then incubated at 37˚C. PPP cuvette was inserted into suitable channel and set to 100% aggregation; 50 μl of aggregation inducing substance was then added. Change in light transmission was considered as resulted aggregation and expressed as % PPP transmission.</p><p>The activity of PC and TAT complex in plasma was assessed by commercial Protein C and TAT complex Elisa kit (Cusabio Biotech Co. LTD). Standard plasma was used for the preparation of standard curves and absorbance was observed at 450 nm. The activity of TAT complex and Protein C in the samples was stated as percentage related to the level of activity of standard plasma. All the tests were performed following NCCL guidelines.</p></sec><sec id="s2_6"><title>2.6. Statistical Analysis</title><p>Software package for statistical analysis (SPSS) version 17 was employed for Data entry and analysis presenting the data as mean &#177; S. E. M with 95% confidence interval. ANOVA followed by post hoc was executed for the comparisons of values with control. The Values of p ≤ 0.05 denote significant and p ≤ 0.005 denote highly significant results.</p></sec></sec><sec id="s3"><title>3. Results</title><p>The results of C. paradisi juice and warfarin on TT, PT, aPTT and Fb are shown in <xref ref-type="table" rid="table1">Table 1</xref>. There was substantially high increase in TT and significant increase in aPTT, however there was noteworthy decrease in Fb level at 0.3 ml/kg of C. paradisias compared to control. However warfarin caused substantially high increase in TT, PT and aPTT and significantly reduced Fb level.</p><p><xref ref-type="table" rid="table2">Table 2</xref> displays result of C. paradisi on aggregation of platelet. There was considerable inhibition in aggregation of platelet by collagen (Col), adenosine phosphate (ADP), arachidonic acid (AA) and epinephrine (Epi) at 0.3 ml/kg dose of C. paradisi. However at 0.5 ml/kg only AA revealed significant inhibition in platelet aggregation.</p><p><xref ref-type="table" rid="table3">Table 3</xref> shows results of C. paradisi in different doses on Protein C and TAT complex. There was considerable rise in Protein C and TAT complex at 0.3 ml/kg, while</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Effects of warfarin and C. paradisi on coagulation factors</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Group/Dose ml/kg</th><th align="center" valign="middle"  colspan="4"  >Parameters</th></tr></thead><tr><td align="center" valign="middle" >TT (Sec)</td><td align="center" valign="middle" >PT (Sec)</td><td align="center" valign="middle" >aPTT (Sec)</td><td align="center" valign="middle" >Fb (mg/dl)</td></tr><tr><td align="center" valign="middle" >Control</td><td align="center" valign="middle" >9.55 &#177; 0.42</td><td align="center" valign="middle" >5.11 &#177; 0.06</td><td align="center" valign="middle" >8.18 &#177; 0.05</td><td align="center" valign="middle" >438.75 &#177; 42.38</td></tr><tr><td align="center" valign="middle" >C. paradisi (0.1)</td><td align="center" valign="middle" >9.20 &#177; 0.13</td><td align="center" valign="middle" >5.22 &#177; 0.02</td><td align="center" valign="middle" >12.51 &#177; 1.82</td><td align="center" valign="middle" >407.07 &#177; 28.65</td></tr><tr><td align="center" valign="middle" >C. paradisi (0.3)</td><td align="center" valign="middle" >12.41 &#177; 0.58**</td><td align="center" valign="middle" >6.35 &#177; 0.73</td><td align="center" valign="middle" >11.46 &#177; 0.31*</td><td align="center" valign="middle" >333.10 &#177; 29.55*</td></tr><tr><td align="center" valign="middle" >C. paradisi (0.5)</td><td align="center" valign="middle" >8.81 &#177; 0.08</td><td align="center" valign="middle" >5.85 &#177; 0.04</td><td align="center" valign="middle" >8.68 &#177; 0.11</td><td align="center" valign="middle" >380.24 &#177; 32.61</td></tr><tr><td align="center" valign="middle" >Warfarin</td><td align="center" valign="middle" >16.57 &#177; 1.74**</td><td align="center" valign="middle" >13.60 &#177; 1.73**</td><td align="center" valign="middle" >15.74 &#177; 1.77**</td><td align="center" valign="middle" >315.39 &#177; 25.54*</td></tr></tbody></table></table-wrap><p>Values, mean &#177; S.E.M. *P ≤ 0.05 significantly unlike as compared to control **P ≤ 0.005 unlike extremely significant as compared to control Warfarin: 5 ml/kg (first three days) and 10 mg/kg (another 3 days).</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Effects of C. paradisi on aggregation of platelet</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Group/Dose ml/kg</th><th align="center" valign="middle"  colspan="4"  >parameters</th></tr></thead><tr><td align="center" valign="middle" >ADP (20 &#181;M)</td><td align="center" valign="middle" >Col (10 &#181;g/ml)</td><td align="center" valign="middle" >Epi (300 &#181;M)</td><td align="center" valign="middle" >AA (500 &#181;g/ml)</td></tr><tr><td align="center" valign="middle" >Control</td><td align="center" valign="middle" >53.85 &#177; 5.36</td><td align="center" valign="middle" >18.20 &#177; 1.15</td><td align="center" valign="middle" >13.89 &#177; 0.97</td><td align="center" valign="middle" >60.84 &#177; 8.38</td></tr><tr><td align="center" valign="middle" >C. paradisi (0.1)</td><td align="center" valign="middle" >44.45 &#177; 0.97</td><td align="center" valign="middle" >22.52 &#177; 1.95</td><td align="center" valign="middle" >11.78 &#177; 1.31</td><td align="center" valign="middle" >61.69 &#177; 8.51</td></tr><tr><td align="center" valign="middle" >C. paradisi (0.3)</td><td align="center" valign="middle" >32.40 &#177; 0.58*</td><td align="center" valign="middle" >10.35 &#177; 0.75*</td><td align="center" valign="middle" >9.38 &#177; 0.49*</td><td align="center" valign="middle" >48.20 &#177; 7.31*</td></tr><tr><td align="center" valign="middle" >C. paradisi (0.5)</td><td align="center" valign="middle" >42.96 &#177; 0.75</td><td align="center" valign="middle" >21.75 &#177; 1.94</td><td align="center" valign="middle" >13.01 &#177; 2.63</td><td align="center" valign="middle" >49.71 &#177; 5.87*</td></tr><tr><td align="center" valign="middle" >Aspirin</td><td align="center" valign="middle" >32.29 &#177; 0.71*</td><td align="center" valign="middle" >10.44 &#177; 0.78*</td><td align="center" valign="middle" >12.84 &#177; 1.53</td><td align="center" valign="middle" >24.51 &#177; 1.18**</td></tr></tbody></table></table-wrap><p>Values, mean &#177; S.E.M. *P ≤ 0.05 significantly unlike as compared to control **P ≤ 0.005 unlike extremely significant as compared to control ADP = Adenosine diphosphate; Col = Collagen; Epi = Epinephrine; AA = Arachidonic acid.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Impact of C. paradisi on protein c and TAT complex</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Group/Dose ml/kg</th><th align="center" valign="middle"  colspan="2"  >parameters</th></tr></thead><tr><td align="center" valign="middle" >Protein C</td><td align="center" valign="middle" >TAT complex</td></tr><tr><td align="center" valign="middle" >Control</td><td align="center" valign="middle" >32.08 &#177; 0.81</td><td align="center" valign="middle" >2.36 &#177; 0.15</td></tr><tr><td align="center" valign="middle" >C. paradisi (0.1)</td><td align="center" valign="middle" >36.25 &#177; 1.59</td><td align="center" valign="middle" >2.71 &#177; 0.14*</td></tr><tr><td align="center" valign="middle" >C. paradisi (0.3)</td><td align="center" valign="middle" >38.96 &#177; 1.48*</td><td align="center" valign="middle" >3.25 &#177; 0.07*</td></tr><tr><td align="center" valign="middle" >C. paradisi (0.5)</td><td align="center" valign="middle" >33.35 &#177; 2.23</td><td align="center" valign="middle" >2.71 &#177; 0.14</td></tr></tbody></table></table-wrap><p>Values, mean &#177; S.E.M. *P ≤ 0.05 significantly dissimilar as compared to control.</p><p>there was no significant change in Protein C and TAT complex at 0.1 ml/kg and 0.5 ml/kg.</p><p><xref ref-type="table" rid="table4">Table 4</xref> shows results of C. paradisi on hematology; at 0.3 ml/kg considerable rise in RBC and hemoglobin was observed, while at 0.5 ml/kg only significant rise in RBC was seen whereas at 0.1 ml/kg no significant change in any hematological factors was observed. However WBC, PLT, hematocrit and mean corpuscle volume were not influenced by any dose of C. paradisi.</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Effect of C. paradisi and aspirin on hematological parameters</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Group/Dose ml/kg</th><th align="center" valign="middle"  colspan="7"  >parameters</th></tr></thead><tr><td align="center" valign="middle" >RBC (x10<sup>5</sup>/cm)</td><td align="center" valign="middle" >WBC (x10<sup>5</sup>/cm)</td><td align="center" valign="middle" >PLT (x10&#179;/cm)</td><td align="center" valign="middle" >Hb (g/dl)</td><td align="center" valign="middle" >Ht (%)</td><td align="center" valign="middle" >MCV (%)</td><td align="center" valign="middle" >MCH (Pg/cell)</td></tr><tr><td align="center" valign="middle" >Control</td><td align="center" valign="middle" >3.84 &#177; 0.3</td><td align="center" valign="middle" >3.32 &#177; 0.4</td><td align="center" valign="middle" >291.04 &#177; 27.6</td><td align="center" valign="middle" >9.77 &#177; 0.4</td><td align="center" valign="middle" >28.23 &#177; 4</td><td align="center" valign="middle" >62.4 &#177; 0.7</td><td align="center" valign="middle" >19.5 &#177; 0.6</td></tr><tr><td align="center" valign="middle" >C. paradisi (0.1)</td><td align="center" valign="middle" >4.68 &#177; 0.4</td><td align="center" valign="middle" >4.14 &#177; 0.4</td><td align="center" valign="middle" >283.10 &#177; 36.7</td><td align="center" valign="middle" >9.90 &#177; 0.2</td><td align="center" valign="middle" >30.21 &#177; 3</td><td align="center" valign="middle" >61.6 &#177; 0.7</td><td align="center" valign="middle" >20.6 &#177; 0.6</td></tr><tr><td align="center" valign="middle" >C. paradisi (0.3)</td><td align="center" valign="middle" >4.95 &#177; 0.3*</td><td align="center" valign="middle" >5.90 &#177; 0.4</td><td align="center" valign="middle" >298.70 &#177; 29.9</td><td align="center" valign="middle" >11 &#177; 0.5*</td><td align="center" valign="middle" >32.38 &#177; 2</td><td align="center" valign="middle" >62.3 &#177; 0.5</td><td align="center" valign="middle" >19.7 &#177; 0.6</td></tr><tr><td align="center" valign="middle" >C. paradisi (0.5)</td><td align="center" valign="middle" >4.82 &#177; 0.3*</td><td align="center" valign="middle" >4.26 &#177; 0.3</td><td align="center" valign="middle" >294.10 &#177; 27.7</td><td align="center" valign="middle" >10.01 &#177; 0.2</td><td align="center" valign="middle" >33.95 &#177; 3</td><td align="center" valign="middle" >61.9 &#177; 0.8</td><td align="center" valign="middle" >20.2 &#177; 0.7</td></tr><tr><td align="center" valign="middle" >Aspirin</td><td align="center" valign="middle" >3.64 &#177; 0.4</td><td align="center" valign="middle" >3.77 &#177; 0.3</td><td align="center" valign="middle" >281.6 &#177; 32.4</td><td align="center" valign="middle" >5.28 &#177; 0.2</td><td align="center" valign="middle" >20.6 &#177; 0.5</td><td align="center" valign="middle" >63.5 &#177; 0.7</td><td align="center" valign="middle" >21.7 &#177; 0.8*</td></tr></tbody></table></table-wrap><p>Values, mean &#177; S.E.M. *P ≤ 0.05 significantly unlike as compared to control Aspirin: 150 mg/kg once daily for 6 days a week.</p></sec><sec id="s4"><title>4. Discussion</title><p>This research was planned particularly to study the effectiveness of C. paradisi on coagulation factors. Dietary flavonoid is one of the herbal components which may alter coagulation and fibrinolysis. It is known that dietary lipids may alter factor VII [<xref ref-type="bibr" rid="scirp.70877-ref37">37</xref>] , fibrinogen, plasminogen activator and tissue plasminogen [<xref ref-type="bibr" rid="scirp.70877-ref38">38</xref>] .</p><p>The risk of bleeding may better be defined by coagulation assay like PT, TT, aPTT and Fb [<xref ref-type="bibr" rid="scirp.70877-ref39">39</xref>] . The effect of C. paradisi juice was thus determined at different doses on platelet count, activated partial thromboplastin time, thrombin time, prothrombin time, and fibrinogen concentration, since these parameters can better define the risk of bleeding [<xref ref-type="bibr" rid="scirp.70877-ref40">40</xref>] , hence were utilized to observe the efficacy of C. paradisi on coagulation process as well as their efficacy in CVD.</p><p>Hepatic synthesis of clotting factors stimulated by increased catabolic rate of prothrombin, results in increased plasma concentration of clotting factors [<xref ref-type="bibr" rid="scirp.70877-ref41">41</xref>] . Therefore it may be concluded that increased concentration of cholesterol may lead to increased plasma concentration of coagulation factors or vice versa.</p><p>One possible explanation of prolonged aPTT could be cholesterol lowering effect of flavonoids and other components. Moreover current investigation revealed remarkable inhibition of platelet aggregation by C. paradisi stimulated by collagen, adenosine diphosphate, arachidonic acid and epinephrine, hence C. paradisi seems to be more effective against thrombosis since existing antiplatelet agents only inhibit thromboxane A2 or ADP platelet activation pathways without interfering number of other platelet activation pathways that may contribute to thrombotic event [<xref ref-type="bibr" rid="scirp.70877-ref42">42</xref>] .</p><p>C. paradisi may have anticoagulant effect due to inhibition of intrinsic coagulation factor and thrombin, since factor IX and X are essentially required for thrombin generation [<xref ref-type="bibr" rid="scirp.70877-ref28">28</xref>] . There is evidence that deficiency of PC and TAT complex leads to cardiovascular events [<xref ref-type="bibr" rid="scirp.70877-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.70877-ref42">42</xref>] [<xref ref-type="bibr" rid="scirp.70877-ref43">43</xref>] . While present outcomes reveals raise in PC and TAT complex, which may lead to inhibition of thrombin activity, prolongation of TT and decrease Fb. hence it may be concluded that C. paradisi may have a beneficial effect in thrombotic disease patients.</p><p>Our result also revealed significant rise in hemoglobin and RBC as compared to control, these beneficial effects of C. paradisi may be due to the presence of flavonoids (hesperidin hesperetin and nobiletin), vitamin C, pyridoxine and iron in citrus fruits reported in several studies [<xref ref-type="bibr" rid="scirp.70877-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.70877-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.70877-ref44">44</xref>] - [<xref ref-type="bibr" rid="scirp.70877-ref48">48</xref>] .</p></sec><sec id="s5"><title>5. Conclusions</title><p>Normal blood flow depends on the balance between pro-coagulant and anti-coagulant factors, unless this balance is shifted towards pro-coagulant mechanisms due to injury or increased vascular sclerosis. Thus present results show that grape fruit juice can act as an effective anticoagulant as it keeps the balance shifted towards anti-coagulant mechanisms.</p><p>These results suggest that addition of C. paradisi juice may be tested by adding to the diet of patients at risk of developing cardiovascular or neurovascular events and may also be helpful in improving the general health of these patients due to high contents of vitamin C, B and phytochemicals such as carotenoids, flavonoids and limonoids.</p></sec><sec id="s6"><title>Acknowledgements</title><p>Authors are thankful to technical staff Department of Pharmacology, University of Karachi for their support during the study.</p></sec><sec id="s7"><title>Conflict of Interest Statement</title><p>None of the author involved in the study has received any financial assistance from any organization and there is no conflict of interest to declare.</p></sec><sec id="s8"><title>Cite this paper</title><p>Mallick, N., Khan, R.A., Riaz, A. and Afroz, S. (2016) Anticoagulant, Antiplatelet and Antianemic Effects of Citrus paradisi (Grape Fruit) Juice in Rabbits. Pharmacology &amp; Pharmacy, 7, 397- 406. http://dx.doi.org/10.4236/pp.2016.71047</p></sec></body><back><ref-list><title>References</title><ref id="scirp.70877-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Dauchet, L., Amouyel, P., Hercberg, S. and Dallongeville, J. (2006) Fruit and Vegetable Consumption and Risk of Coronary Heart Disease: A Meta-Analysis of Cohort Studies. Journal of Nutrition, 136, 2588-2593.</mixed-citation></ref><ref id="scirp.70877-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Johnsen, S.P., Overvad, K., Stripp, C., Tj&amp;#216;nneland, A., Husted, S.E. and S&amp;#216;rensen, H.T. (2003) Intake of Fruits and Vegetables and the Risk of Ischemic Stroke in a Cohort of Danish Men and Women. The American Journal of Clinical Nutrition, 78, 57-64.</mixed-citation></ref><ref id="scirp.70877-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, M., Duan, C., Zang, Y., Huang, Z. and Liu, G. (2011) The Flavonoid Composition of Flavedo and Juice from the Pummelo Cultivar Citrus grandis (L.) Osbeck and the Grapefruit Cultivar Citrus paradise from China. Food Chemistry, 129, 1530-1536.  
http://dx.doi.org/10.1016/j.foodchem.2011.05.136</mixed-citation></ref><ref id="scirp.70877-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kelebek, H. (2010) Sugars, Organic Acids, Phenolic Compositions and Antioxidant Activity of Grapefruit Citrus paradisi Cultivars Grown in Turkey. Industrial Crops and Products, 32, 269-274. http://dx.doi.org/10.1016/j.indcrop.2010.04.023</mixed-citation></ref><ref id="scirp.70877-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Armando, C., Maythe, S. and Beatriz, N.P. (1998) Antioxidant Activity of Grapefruit Seed Extract on Vegetable Oils. Journal of the Science of Food and Agriculture, 77, 463-467.  
http://dx.doi.org/10.1002/(SICI)1097-0010(199808)77:4&lt;463::AID-JSFA62&gt;3.0.CO;2-1</mixed-citation></ref><ref id="scirp.70877-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ridker, P.M., Stampfer, M.J. and Rifai, N. (2001) Novel Risk Factors for Systemic Atherosclerosis: A Comparison of C-Reactive Protein, Fibrinogen, Homocysteine, Lipoprotein(a), and Standard Cholesterol Screening as Predictors of Peripheral Arterial Disease. JAMA, 285, 2481-2485. http://dx.doi.org/10.1001/jama.285.19.2481</mixed-citation></ref><ref id="scirp.70877-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ridker, P.M. (1999) Evaluating Novel Cardiovascular Risk Factors. Ann Intern Med., 130, 933-937. http://dx.doi.org/10.7326/0003-4819-130-11-199906010-00018</mixed-citation></ref><ref id="scirp.70877-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Smith, S.C., Greenland, P. and Grundy, S. (2000) Beyond Secondary Prevention: Identifying the High-Risk Patient for Primary Prevention: Executive Summary. Circulation, 101, 111-116. http://dx.doi.org/10.1161/01.CIR.101.1.111</mixed-citation></ref><ref id="scirp.70877-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Grundy, S.M., Bazzarre, T., Cleeman, J., D’Agostino, R.B., Hill, M., Houston-Miller, N., Kannel, W.B., Krauss, R., Krumholz, H.M., Lauer, R.M., Ockene, I.S., Pasternak, R.C., Pearson, T., Ridker, P.M. and Wood, D. (2000) Prevention Conference V: Beyond Secondary Prevention: Identifying the High-Risk Patient for Primary Prevention: Medical Office Assessment. Writing Group I. Circulation, 101, e3-e11.  
http://dx.doi.org/10.1161/01.CIR.101.1.e3</mixed-citation></ref><ref id="scirp.70877-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Little, W.J., Miller, S.C., Henry, G.R. and McIntosh, B.A. (2002) Antithrombotic Agents: Implication in Dentistry. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 93, 544-551. http://dx.doi.org/10.1067/moe.2002.121391</mixed-citation></ref><ref id="scirp.70877-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X.K., Hsu, M.-Y., Steinbacher, T.E., Monticello, T.M. and Schumacher, W.A. (2007) Quantification of Platelet Composition in Experimental Venous Thrombosis by Real-Time Polymerase Chain Reaction. Thrombosis Research, 119, 593-600.  
http://dx.doi.org/10.1016/j.thromres.2006.04.011</mixed-citation></ref><ref id="scirp.70877-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ahmed, A., Khan, R.A. and Mesaik, M.A. (2009) Anti-Inflammatory Effect of Natural Honey on Bovine Thrombin Induced Oxidative Burst in Phagocytes. Phytotherapy Research, 23, 801-808. http://dx.doi.org/10.1002/ptr.2648</mixed-citation></ref><ref id="scirp.70877-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Riaz, A., Khan, R.A. and Ahmed, S.P. (2009) Assessment of Anticoagulant Effect of Evening Primrose Oil. Pakistan Journal of Pharmaceutical Sciences, 22, 355-359.</mixed-citation></ref><ref id="scirp.70877-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Abdullah, W.Z., Moufak, S.K., Yusof, Z., Mohamad, M.S. and Kamarul, I.M. (2010) Shortened Activated Partial Thromboplastin Time, a Hemostatic Marker for Hypercoagulable State during Acute Coronary Event. Translational Research, 155, 315-319.  
http://dx.doi.org/10.1016/j.trsl.2010.02.001</mixed-citation></ref><ref id="scirp.70877-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Heiss, C., Kleinbongard, P., Dejam, A., Perre, S., Schroeter, H., Sies, H. and Kelm, M. (2005) Acute Consumption of Flavanol-Rich Cocoa and the Reversal of Endothelial Dysfunction in Smokers. Journal of the American College of Cardiology, 46, 1276-1283.  
http://dx.doi.org/10.1016/j.jacc.2005.06.055</mixed-citation></ref><ref id="scirp.70877-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">McCullough, M.L., Peterson, J.J., Patel, R., Jacques, P.F., Shah, R. and Dwyer, J.T. (2012) Flavonoid Intake and Cardiovascular Disease Mortality in a Prospective Cohort of US Adults. American Journal of Clinical Nutrition, 95, 454-464.  
http://dx.doi.org/10.3945/ajcn.111.016634</mixed-citation></ref><ref id="scirp.70877-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Kim, H.P., Son, K.H., Chang, H.W. and Kang, S.S. (2004) Anti-Inflammatory Plant Flavonoids and Cellular Action Mechanisms. Journal of Pharmacological Sciences, 96, 229-245.  
http://dx.doi.org/10.1254/jphs.CRJ04003X</mixed-citation></ref><ref id="scirp.70877-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Chun, O.K., Chung, S.J., Claycombe, K.J. and Song, W.O. (2008) Serum C-Reactive Protein Concentrations Are Inversely Associated with Dietary Flavonoid Intake in US Adults. Journal of Nutrition, 138, 753-760.</mixed-citation></ref><ref id="scirp.70877-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Grassi, D., Desideri, G. and Ferri, C. (2010) Flavonoids: Antioxidants against Atherosclerosis. Nutrients, 2, 889-902. http://dx.doi.org/10.3390/nu2080889</mixed-citation></ref><ref id="scirp.70877-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Hernandez, M.V., Montes, M.M.A. and Elizalde, G.M.P. (2009) Study of the Thermal Degradation of Citrus Seeds. Biomass and Bioenergy, 33, 1295-1299.  
http://dx.doi.org/10.1016/j.biombioe.2009.05.016</mixed-citation></ref><ref id="scirp.70877-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Gonzalez, M.E., Domínguez, P.R., Moreno, D.A. and García, V.C. (2010) Natural Bioactive Compounds of Citrus limon for Food and Health. Journal of Pharmaceutical and Biomedical Analysis, 51, 327-345. http://dx.doi.org/10.1016/j.jpba.2009.07.027</mixed-citation></ref><ref id="scirp.70877-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Vazquez, P.R.L., Martinez, D.E., Perona, S.J. and Ruiz, G.V. (2004) Effect of Different Dietary Oils on Inflammatory Mediator Generation and Fatty Acid Composition in Rat Neutrophils. Metabolism, 53, 59-65. http://dx.doi.org/10.1016/j.metabol.2003.08.010</mixed-citation></ref><ref id="scirp.70877-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Pfister, S.L. (2006) Aortic Thromboxane Receptor Deficiency Alters Vascular Reactivity in Cholesterol-Fed Rabbits. Atherosclerosis, 189, 358-363.  
http://dx.doi.org/10.1016/j.atherosclerosis.2006.02.004</mixed-citation></ref><ref id="scirp.70877-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Son, D.J., Lee, H.W., Shin, H.W., Lee, J.J., Yoo, H.S., Kim, T.J., Yun, Y.P. and Hong, J.T. (2008) Enhanced Release of Sphingosine-1-Phosphate from Hypercholesterolemic Platelets: Role in Development of Hypercholesterolemic Atherosclerosis. Prostaglandins, Leukotrienes and Essential Fatty Acids, 78, 383-390. http://dx.doi.org/10.1016/j.plefa.2008.04.010</mixed-citation></ref><ref id="scirp.70877-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Giovannucci, E., Rimm, E.B., Liu, Y., Stampfer, M.J. and Willett, W.C. (2002) A Prospective Study of Tomato Products, Lycopene, and Prostate Cancer Risk. Journal of the National Cancer Institute, 94, 391-398. http://dx.doi.org/10.1093/jnci/94.5.391</mixed-citation></ref><ref id="scirp.70877-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Gorinstein, S., Caspi, A., Libman, I., Lerner, H.T., Huang, D., Leontowicz, H., Leontowicz, M., Tashma, Z., Katrich, E., Feng, S. and Trakhtenberg, S. (2006) Red Grapefruit Positively Influences Serum Triglyceride Level in Patients Suffering from Coronary Atherosclerosis: Studies in Vitro and in Humans. Journal of Agricultural and Food Chemistry, 54, 1887-1892. http://dx.doi.org/10.1021/jf058171g</mixed-citation></ref><ref id="scirp.70877-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Danckwardt, S., Hentze, M.W. and Kulozik, A.E. (2013) Pathologies at the Nexus of Blood Coagulation and Inflammation: Thrombin in Hemostasis, Cancer and Beyond. Journal of Molecular Medicine, 91, 1257-1271. http://dx.doi.org/10.1007/s00109-013-1074-5</mixed-citation></ref><ref id="scirp.70877-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Di Cera, E. (2008) Thrombin Review. Molecular Aspects of Medicine, 29, 203-254.  
http://dx.doi.org/10.1016/j.mam.2008.01.001</mixed-citation></ref><ref id="scirp.70877-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Merchant, M.A. and Modi, D.N. (2004) Acute and Chronic Effects of Aspirin on Hematological Parameters and Hepatic Ferritin Expression in Mice. Indian Journal of Pharmacology, 36, 226-230.</mixed-citation></ref><ref id="scirp.70877-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Warfarin Dosing Guideline (2009) Guidelines Were Prepared by the Department of Surgical Education, Orlando Regional Medical Center. www.SurgicalCriticalCare.net</mixed-citation></ref><ref id="scirp.70877-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Wayne, P.A. (1998) Collection, Transport and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays. 3rd Edition, Approved Guideline H21-A2, National Committee for Clinical Laboratory Standards, NCCLS Document H21-A3.</mixed-citation></ref><ref id="scirp.70877-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Clauss, A. (1957) Rapid Physiological Coagulation Method in Determination of Fibrinogen. Acta Haematologica, 17, 237-246. http://dx.doi.org/10.1159/000205234</mixed-citation></ref><ref id="scirp.70877-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">McNerlan, S.E., Crawford, V.L. and Stout, R.W. (1997) Measurement of Fibrinogen in Frozen Plasma. Thrombosis Research, 88, 481-484.  
http://dx.doi.org/10.1016/S0049-3848(97)00283-1</mixed-citation></ref><ref id="scirp.70877-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Kim, H.P., Park, H., Son, K.H., Chang, H.W. and Kang, S.S. (2008) Biochemical Pharmacology of Biflavonoids: Implications for Anti-Inflammatory Action. Archives of Pharmacal Research, 31, 265-273. http://dx.doi.org/10.1007/s12272-001-1151-3</mixed-citation></ref><ref id="scirp.70877-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Jeon, S.M., Park, Y.B. and Choi, M.S. (2004) Antihypercholesterolemic Property of Naringin Alters Plasma and Tissue Lipids, Cholesterol-Regulating Enzymes, Fecal Sterol and Tissue Morphology in Rabbits. Clinical Nutrition, 23, 1025-1034.  
http://dx.doi.org/10.1016/j.clnu.2004.01.006</mixed-citation></ref><ref id="scirp.70877-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Riaz, A., Khan, R.A. and Ahmed, M. (2013) Glycemic Response of Citrus limon. Pomegranate and Their Combinations in Alloxan Induced Diabetic Rats. Australian Journal of Basic and Applied Sciences, 7, 215-219.</mixed-citation></ref><ref id="scirp.70877-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Bladbjerg, E.M., Marckmann, P., Sandstrom, B. and Jespersen, J. (1994) Non-Fasting Factor VII Coagulant Activity (FVII: C) Increased by High Fat Diet. Thrombosis and Haemostasis, 71, 755-778.</mixed-citation></ref><ref id="scirp.70877-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Allman-Farinelli, M.A., Hall, D., Kingham, K., Pang, D., Petocz, P. and Favaloro, E.J. (1999) Comparison of the Effects of Two Low Fat Diets with Different α Linolenic: Linoleic Acid Ratios on Coagulation and Fibrinolysis. Atherosclerosis, 142, 159-168.  
http://dx.doi.org/10.1016/S0021-9150(98)00233-0</mixed-citation></ref><ref id="scirp.70877-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Gentry, P.A. (2004) Comparative Aspects of Blood Coagulation. Veterinary Journal, 168, 238-251. http://dx.doi.org/10.1016/j.tvjl.2003.09.013</mixed-citation></ref><ref id="scirp.70877-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Stanworth, S.J. (2007) The Evidence-Based Use of FFP and Cryoprecipitate for Abnormalities of Coagulation Tests and Clinical Coagulopathy. Hematology, 179-186.</mixed-citation></ref><ref id="scirp.70877-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Miller, G.J. (2005) Dietary Fatty Acids and the Haemostatic System. Atherosclerosis, 179, 213-227. http://dx.doi.org/10.1016/j.atherosclerosis.2004.10.010</mixed-citation></ref><ref id="scirp.70877-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Previtali, E., Bucciarelli, P., Passamonti, S.M. and Martinelli, I. (2011) Risk Factors for Venous and Arterial Thrombosis. Blood Transfusion, 9, 120-138.</mixed-citation></ref><ref id="scirp.70877-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Monforte, M.T., Trovato, A., Kirjavainen, S., Forestieri, A.M., Galati, E.M. and Lo Curto, R.B. (1995) Biological Effects of Hesperidin, a Citrus flavonoid. (Note II): Hypolipidemic Activity on Experimental Hypercholesterolemia in Rat. Farmaco, 50, 595-599.</mixed-citation></ref><ref id="scirp.70877-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Kelebek, H., Selli, S., Canbas, A. and Cabaroglu, T. (2009) HPLC Determination of Organic Acids, Sugars, Phenolic Compositions and Antioxidant Capacity of Orange Juice and Orange Wine Made from a Turkish cv. Kozan. Microchemical Journal, 91, 187-192.  
http://dx.doi.org/10.1016/j.microc.2008.10.008</mixed-citation></ref><ref id="scirp.70877-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Violi, F., Pignatelli, P. and Basili, S. (2010) Nutrition, Supplements, and Vitamins in Platelet Function and Bleeding. Circulation, 121, 1033-1044.  
http://dx.doi.org/10.1161/CIRCULATIONAHA.109.880211</mixed-citation></ref><ref id="scirp.70877-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Bojic, M., Debeljak, Z., Tomicic, M., Medic-Saric, M. and Tomic, S. (2011) Evaluation of Anti-Aggregatory Activity of Flavonoid Aglycone Series. Nutrition Journal, 10, 73.  
http://dx.doi.org/10.1186/1475-2891-10-73</mixed-citation></ref><ref id="scirp.70877-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X., Li, W. and Wang, H. (2006) More Tea for Septic Patients?—Green Tea May Reduce Endotoxin-Induced Release of High Mobility Group Box 1 and Other Pro-Inflammatory Cytokines. Medical Hypotheses, 66, 660-603.  
http://dx.doi.org/10.1016/j.mehy.2005.09.025</mixed-citation></ref><ref id="scirp.70877-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Teng, C.M., Li, H.L., Wu, T.S., Huang, S.C. and Huang, T.F. (1992) Antiplatelet Actions of Some Coumarin Compounds Isolated from Plant Sources. Thrombosis Research, 66, 549-557. http://dx.doi.org/10.1016/0049-3848(92)90309-X</mixed-citation></ref></ref-list></back></article>